Clinical trial
A Phase II Investigator Sponsored Multi-Centre Trial of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Patients With Relapsed or Refractory Marginal Zone Lymphoma
NCT03093831 is registered in ClinicalTrials.gov with National Cancer Centre, Singapore as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Investigator Sponsored Multi-Centre Trial of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Patients With Relapsed or Refractory Marginal Zone Lymphoma
- Lead sponsor
- National Cancer Centre, Singapore
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- July 8, 2016
- Completion date
- July 17, 2020
- Enrollment
- 5 (actual)
- Sites
- 2
Conditions
As the registry lists them; a condition with its own page is linked.